High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort

Our aim was to test the prediction and clinical applicability of high-sensitivity assayed troponin I for incident cardiovascular events in a general middle-aged European population. High-sensitivity assayed troponin I was measured in the Scottish Heart Health Extended Cohort (n = 15 340) with 2171 c...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	European heart journal Ročník 35; číslo 5; s. 271
Hlavní autoři:	Zeller, Tanja, Tunstall-Pedoe, Hugh, Saarela, Olli, Ojeda, Francisco, Schnabel, Renate B, Tuovinen, Tarja, Woodward, Mark, Struthers, Allan, Hughes, Maria, Kee, Frank, Salomaa, Veikko, Kuulasmaa, Kari, Blankenberg, Stefan
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.02.2014
Témata:	Biomarkers - blood Cardiovascular Diseases - blood Cardiovascular Diseases - mortality Cohort Studies Female Humans Immunoassay - methods Male Middle Aged Myocardial Infarction - blood Myocardial Infarction - mortality Prevalence Risk Assessment Scotland - epidemiology Sex Distribution Stroke - blood Stroke - mortality Troponin I - blood Scotland High-sensitivity assayed troponin I MONICA Risk Genetics Archiving and Monograph (MORGAM) Mortality Cardiovascular risk Scottish Heart Health Extended Cohort (SHHEC)
ISSN:	1522-9645, 1522-9645
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Our aim was to test the prediction and clinical applicability of high-sensitivity assayed troponin I for incident cardiovascular events in a general middle-aged European population. High-sensitivity assayed troponin I was measured in the Scottish Heart Health Extended Cohort (n = 15 340) with 2171 cardiovascular events (including acute coronary heart disease and probable ischaemic strokes), 714 coronary deaths (25% of all deaths), 1980 myocardial infarctions, and 797 strokes of all kinds during an average of 20 years follow-up. Detection rate above the limit of detection (LoD) was 74.8% in the overall population and 82.6% in men and 67.0% in women. Troponin I assayed by the high-sensitivity method was associated with future cardiovascular risk after full adjustment such as that individuals in the fourth category had 2.5 times the risk compared with those without detectable troponin I (P < 0.0001). These associations remained significant even for those individuals in whom levels of contemporary-sensitivity troponin I measures were not detectable. Addition of troponin I levels to clinical variables led to significant increases in risk prediction with significant improvement of the c-statistic (P < 0.0001) and net reclassification (P < 0.0001). A threshold of 4.7 pg/mL in women and 7.0 pg/mL in men is suggested to detect individuals at high risk for future cardiovascular events. Troponin I, measured with a high-sensitivity assay, is an independent predictor of cardiovascular events and might support selection of at risk individuals.
AbstractList	Our aim was to test the prediction and clinical applicability of high-sensitivity assayed troponin I for incident cardiovascular events in a general middle-aged European population. High-sensitivity assayed troponin I was measured in the Scottish Heart Health Extended Cohort (n = 15 340) with 2171 cardiovascular events (including acute coronary heart disease and probable ischaemic strokes), 714 coronary deaths (25% of all deaths), 1980 myocardial infarctions, and 797 strokes of all kinds during an average of 20 years follow-up. Detection rate above the limit of detection (LoD) was 74.8% in the overall population and 82.6% in men and 67.0% in women. Troponin I assayed by the high-sensitivity method was associated with future cardiovascular risk after full adjustment such as that individuals in the fourth category had 2.5 times the risk compared with those without detectable troponin I (P < 0.0001). These associations remained significant even for those individuals in whom levels of contemporary-sensitivity troponin I measures were not detectable. Addition of troponin I levels to clinical variables led to significant increases in risk prediction with significant improvement of the c-statistic (P < 0.0001) and net reclassification (P < 0.0001). A threshold of 4.7 pg/mL in women and 7.0 pg/mL in men is suggested to detect individuals at high risk for future cardiovascular events. Troponin I, measured with a high-sensitivity assay, is an independent predictor of cardiovascular events and might support selection of at risk individuals. Our aim was to test the prediction and clinical applicability of high-sensitivity assayed troponin I for incident cardiovascular events in a general middle-aged European population.AIMSOur aim was to test the prediction and clinical applicability of high-sensitivity assayed troponin I for incident cardiovascular events in a general middle-aged European population.High-sensitivity assayed troponin I was measured in the Scottish Heart Health Extended Cohort (n = 15 340) with 2171 cardiovascular events (including acute coronary heart disease and probable ischaemic strokes), 714 coronary deaths (25% of all deaths), 1980 myocardial infarctions, and 797 strokes of all kinds during an average of 20 years follow-up. Detection rate above the limit of detection (LoD) was 74.8% in the overall population and 82.6% in men and 67.0% in women. Troponin I assayed by the high-sensitivity method was associated with future cardiovascular risk after full adjustment such as that individuals in the fourth category had 2.5 times the risk compared with those without detectable troponin I (P < 0.0001). These associations remained significant even for those individuals in whom levels of contemporary-sensitivity troponin I measures were not detectable. Addition of troponin I levels to clinical variables led to significant increases in risk prediction with significant improvement of the c-statistic (P < 0.0001) and net reclassification (P < 0.0001). A threshold of 4.7 pg/mL in women and 7.0 pg/mL in men is suggested to detect individuals at high risk for future cardiovascular events.METHODS AND RESULTSHigh-sensitivity assayed troponin I was measured in the Scottish Heart Health Extended Cohort (n = 15 340) with 2171 cardiovascular events (including acute coronary heart disease and probable ischaemic strokes), 714 coronary deaths (25% of all deaths), 1980 myocardial infarctions, and 797 strokes of all kinds during an average of 20 years follow-up. Detection rate above the limit of detection (LoD) was 74.8% in the overall population and 82.6% in men and 67.0% in women. Troponin I assayed by the high-sensitivity method was associated with future cardiovascular risk after full adjustment such as that individuals in the fourth category had 2.5 times the risk compared with those without detectable troponin I (P < 0.0001). These associations remained significant even for those individuals in whom levels of contemporary-sensitivity troponin I measures were not detectable. Addition of troponin I levels to clinical variables led to significant increases in risk prediction with significant improvement of the c-statistic (P < 0.0001) and net reclassification (P < 0.0001). A threshold of 4.7 pg/mL in women and 7.0 pg/mL in men is suggested to detect individuals at high risk for future cardiovascular events.Troponin I, measured with a high-sensitivity assay, is an independent predictor of cardiovascular events and might support selection of at risk individuals.CONCLUSIONTroponin I, measured with a high-sensitivity assay, is an independent predictor of cardiovascular events and might support selection of at risk individuals.
Author	Schnabel, Renate B Kee, Frank Woodward, Mark Hughes, Maria Tunstall-Pedoe, Hugh Ojeda, Francisco Zeller, Tanja Saarela, Olli Blankenberg, Stefan Tuovinen, Tarja Kuulasmaa, Kari Salomaa, Veikko Struthers, Allan
Author_xml	– sequence: 1 givenname: Tanja surname: Zeller fullname: Zeller, Tanja organization: Clinic for General and Interventional Cardiology, University Heart Centre Hamburg, Hamburg, Germany – sequence: 2 givenname: Hugh surname: Tunstall-Pedoe fullname: Tunstall-Pedoe, Hugh – sequence: 3 givenname: Olli surname: Saarela fullname: Saarela, Olli – sequence: 4 givenname: Francisco surname: Ojeda fullname: Ojeda, Francisco – sequence: 5 givenname: Renate B surname: Schnabel fullname: Schnabel, Renate B – sequence: 6 givenname: Tarja surname: Tuovinen fullname: Tuovinen, Tarja – sequence: 7 givenname: Mark surname: Woodward fullname: Woodward, Mark – sequence: 8 givenname: Allan surname: Struthers fullname: Struthers, Allan – sequence: 9 givenname: Maria surname: Hughes fullname: Hughes, Maria – sequence: 10 givenname: Frank surname: Kee fullname: Kee, Frank – sequence: 11 givenname: Veikko surname: Salomaa fullname: Salomaa, Veikko – sequence: 12 givenname: Kari surname: Kuulasmaa fullname: Kuulasmaa, Kari – sequence: 13 givenname: Stefan surname: Blankenberg fullname: Blankenberg, Stefan
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/24104876$$D View this record in MEDLINE/PubMed
BookMark	eNpNUEtPwzAMjhCIMeDOCfnIpZC0adpygwkYEgjE4zylqUsz2qQk6aT9IX4nFRsSl8-W9T1sT8musQYJOWH0nNEiucDBNShdWF5gEzgVO-SApXEcFYKnu__6CZl6v6SU5oKJfTKJOaM8z8QB-Z7rjwZ62w-tDNoa6B2uZItGIdgalHSVlgqCs7012sA9dCj94LCCcg0SmlEeeTReB73SYRx5L0c01UZrV9Kr0duB0_4T0Afd_QZdQmgQHp9e7q4e4VrbTrpPdPDs7BJVgFdlQ9C-gZltrAtHZK-WrcfjbT0k77c3b7N59PB0dz-7eohUItIQpWmtMMMaC0WTvIxRxbTmpcIYC1ZUYkTGa5aWNEuzXFFaZTJLyhJFIpNa5fEhOdv49s5-DeO2i057hW0rDdrBLxgveEKTlIuRerqlDmWH1aJ342Vuvfj7bfwD-QyDtQ
CitedBy_id	crossref_primary_10_1016_j_jjcc_2024_03_005 crossref_primary_10_1093_eurheartj_ehw172 crossref_primary_10_1016_j_ijcard_2016_12_167 crossref_primary_10_1161_CIRCULATIONAHA_119_042866 crossref_primary_10_1002_ejhf_663 crossref_primary_10_3389_fcvm_2022_1054959 crossref_primary_10_3390_biom12101496 crossref_primary_10_2217_fca_15_39 crossref_primary_10_1177_0004563215619946 crossref_primary_10_2217_bmm_14_54 crossref_primary_10_1136_heartjnl_2019_314892 crossref_primary_10_3389_fcvm_2020_617705 crossref_primary_10_1373_clinchem_2014_234369 crossref_primary_10_1056_NEJMoa1803377 crossref_primary_10_1161_JAHA_117_007914 crossref_primary_10_1161_STROKEAHA_120_029628 crossref_primary_10_1097_MD_0000000000005703 crossref_primary_10_1093_ije_dyv092 crossref_primary_10_1002_ejhf_273 crossref_primary_10_1016_j_ijcard_2019_01_107 crossref_primary_10_1016_j_hlc_2015_09_001 crossref_primary_10_1515_cclm_2023_0336 crossref_primary_10_2217_bmm_16_7 crossref_primary_10_1016_j_cca_2014_08_016 crossref_primary_10_1038_s41598_018_26120_1 crossref_primary_10_1177_2047487316638201 crossref_primary_10_1093_cvr_cvae067 crossref_primary_10_1186_s11556_023_00313_8 crossref_primary_10_2337_dc19_1327 crossref_primary_10_1016_j_ejim_2022_01_012 crossref_primary_10_1161_CIRCOUTCOMES_117_004227 crossref_primary_10_1093_clinchem_hvaa023 crossref_primary_10_1016_j_clinbiochem_2015_04_013 crossref_primary_10_7326_M18_0670 crossref_primary_10_1001_jama_2024_5596 crossref_primary_10_1093_ajh_hpu226 crossref_primary_10_1111_eci_13532 crossref_primary_10_1016_j_atherosclerosis_2015_12_017 crossref_primary_10_1161_CIRCULATIONAHA_123_066199 crossref_primary_10_1016_j_jcmg_2016_11_021 crossref_primary_10_1111_echo_15411 crossref_primary_10_1373_clinchem_2016_261172 crossref_primary_10_1007_s00392_016_1026_5 crossref_primary_10_1016_j_athplu_2024_09_003 crossref_primary_10_1016_j_jacc_2017_05_062 crossref_primary_10_1016_j_jstrokecerebrovasdis_2021_106267 crossref_primary_10_1515_cclm_2020_1433 crossref_primary_10_1016_j_endien_2021_08_005 crossref_primary_10_1136_heartjnl_2017_312093 crossref_primary_10_1007_s11883_016_0566_5 crossref_primary_10_1373_clinchem_2015_244160 crossref_primary_10_1093_eurheartj_eht479 crossref_primary_10_1161_CIRCULATIONAHA_114_014522 crossref_primary_10_1161_JAHA_117_007297 crossref_primary_10_1161_CIR_0000000000000490 crossref_primary_10_2217_bmm_2019_0039 crossref_primary_10_1016_j_endinu_2020_05_007 crossref_primary_10_1016_j_amjcard_2018_02_039 crossref_primary_10_1136_heartasia_2016_010818 crossref_primary_10_3389_fmed_2025_1624682 crossref_primary_10_1186_s12872_023_03231_w crossref_primary_10_1373_clinchem_2014_222778 crossref_primary_10_1007_s00296_022_05204_2 crossref_primary_10_1016_j_drugalcdep_2016_11_039 crossref_primary_10_1016_j_pathol_2017_03_004 crossref_primary_10_1007_s11886_014_0471_x crossref_primary_10_1016_j_annemergmed_2016_05_023 crossref_primary_10_1038_nrcardio_2015_105 crossref_primary_10_1016_j_amjcard_2016_06_043 crossref_primary_10_1038_srep18320 crossref_primary_10_1097_EE9_0000000000000078 crossref_primary_10_1093_eurjpc_zwad122 crossref_primary_10_1016_j_amjmed_2015_10_016 crossref_primary_10_2174_0929867330666230315152045 crossref_primary_10_1016_j_cca_2015_03_002 crossref_primary_10_1080_10408363_2018_1525335 crossref_primary_10_1016_j_biopha_2021_112493 crossref_primary_10_1373_clinchem_2017_271684 crossref_primary_10_1136_heartjnl_2015_309136 crossref_primary_10_1515_cclm_2014_0619 crossref_primary_10_1093_rheumatology_key057 crossref_primary_10_1016_j_ijcard_2018_12_001 crossref_primary_10_1093_ofid_ofad234 crossref_primary_10_1371_journal_pone_0307468 crossref_primary_10_1177_2047487315618796 crossref_primary_10_1161_JAHA_118_011028 crossref_primary_10_1136_heartjnl_2014_305968 crossref_primary_10_1007_s11892_015_0661_y crossref_primary_10_1183_13993003_01314_2019 crossref_primary_10_1016_j_jacc_2018_06_051 crossref_primary_10_1159_000510619 crossref_primary_10_2459_JCM_0000000000001155 crossref_primary_10_1161_STROKEAHA_114_007858 crossref_primary_10_3390_ijms23105680 crossref_primary_10_7759_cureus_35865 crossref_primary_10_1016_j_heliyon_2023_e20643 crossref_primary_10_1080_14779072_2016_1176528 crossref_primary_10_1016_j_amjcard_2018_01_004 crossref_primary_10_1016_j_clinbiochem_2014_11_014 crossref_primary_10_1373_clinchem_2016_262659 crossref_primary_10_1016_j_amjmed_2023_05_009 crossref_primary_10_1136_heartjnl_2016_309484 crossref_primary_10_1016_j_cjca_2019_08_022 crossref_primary_10_1161_JAHA_119_015515 crossref_primary_10_1016_j_ijcard_2015_07_106 crossref_primary_10_1016_j_ijcard_2016_07_166 crossref_primary_10_1371_journal_pone_0174166 crossref_primary_10_1016_j_ijcard_2017_01_021 crossref_primary_10_3389_fcvm_2022_895421 crossref_primary_10_1161_JAHA_116_004174 crossref_primary_10_3390_life13020267 crossref_primary_10_1016_j_metabol_2014_10_028 crossref_primary_10_1007_s00380_017_0948_9 crossref_primary_10_1097_HJH_0000000000002497 crossref_primary_10_1161_JAHA_118_011882 crossref_primary_10_1016_j_jcmg_2017_01_017 crossref_primary_10_1007_s11883_014_0427_z crossref_primary_10_1038_s41598_018_23441_z crossref_primary_10_1002_jcla_22294 crossref_primary_10_15829_1728_8800_2020_2584 crossref_primary_10_1016_j_clinbiochem_2014_11_010 crossref_primary_10_1161_JAHA_122_027166 crossref_primary_10_3390_medicina59101759 crossref_primary_10_1161_CIRCULATIONAHA_116_023726 crossref_primary_10_1161_HYPERTENSIONAHA_115_06501 crossref_primary_10_15420_japsc_2023_34 crossref_primary_10_1515_cclm_2020_0310 crossref_primary_10_2217_bmm_2016_0098 crossref_primary_10_1111_acem_14897 crossref_primary_10_1161_STROKEAHA_119_028323 crossref_primary_10_2459_JCM_0000000000000811 crossref_primary_10_1093_ehjopen_oeac006 crossref_primary_10_1093_eurheartj_ehx457 crossref_primary_10_1016_j_annemergmed_2023_04_024 crossref_primary_10_1093_eurjpc_zwae374 crossref_primary_10_1016_j_clinbiochem_2018_05_003 crossref_primary_10_1093_eurheartj_ehae178 crossref_primary_10_1016_j_tcm_2016_06_002 crossref_primary_10_1093_eurheartj_ehv721 crossref_primary_10_1177_00045632221100347 crossref_primary_10_1161_STROKEAHA_120_029452 crossref_primary_10_1097_HCO_0000000000000081 crossref_primary_10_23736_S1825_859X_21_00111_0 crossref_primary_10_3390_diagnostics14010087 crossref_primary_10_1373_clinchem_2017_275289 crossref_primary_10_1016_j_jacc_2016_10_020
ContentType	Journal Article
CorporateAuthor	MORGAM Investigators
CorporateAuthor_xml	– name: MORGAM Investigators
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1093/eurheartj/eht406
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1522-9645
ExternalDocumentID	24104876
Genre	Research Support, Non-U.S. Gov't Journal Article
GeographicLocations	Scotland
GeographicLocations_xml	– name: Scotland
GrantInformation_xml	– fundername: Chief Scientist Office – fundername: Medical Research Council grantid: MR/K023241/1 – fundername: Medical Research Council grantid: G0601463 – fundername: British Heart Foundation
GroupedDBID	--- --K -E4 .2P .GJ .I3 .XZ .ZR 08P 0R~ 18M 1B1 1TH 29G 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 70D AABZA AACZT AAFWJ AAJKP AAJQQ AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWDT ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNGD ABNHQ ABNKS ABOCM ABPQP ABPTD ABQLI ABQNK ABSMQ ABVGC ABWST ABXVV ABZBJ ACFRR ACGFO ACGFS ACPQN ACPRK ACUFI ACUKT ACUTJ ACUTO ACVCV ACYHN ACZBC ADBBV ADEYI ADEZT ADGHP ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEHUL AEJOX AEKPW AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFQV AFFZL AFIYH AFOFC AFSHK AFXAL AFYAG AGINJ AGKEF AGKRT AGMDO AGORE AGQPQ AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AI. AIAGR AIJHB AJBYB AJDVS AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APJGH APWMN AQDSO AQKUS ASPBG ATGXG ATTQO AVNTJ AVWKF AXUDD AZFZN BAWUL BAYMD BCGUY BCRHZ BEYMZ BHONS BTRTY BVRKM BZKNY C1A C45 CAG CDBKE CGR COF CS3 CUY CVF CZ4 DAKXR DIK DILTD D~K E3Z EBS ECM EE~ EIF EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IHE IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M41 MBLQV MHKGH ML0 N4W N9A NGC NOMLY NOYVH NPM NQ- NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OB3 OBFPC OCZFY ODMLO OGROG OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RIG RNI ROL ROX ROZ RPZ RUSNO RW1 RXO RZF SEL TCURE TEORI TJX TMA UHS VH1 W8F WOQ X7H YAYTL YKOAZ YXANX ZGI ZKX ~91 7X8
ID	FETCH-LOGICAL-c365t-55fce7efe9c038b2ec20f4bce2e919d6e9114f15b07578c00d7a73bbe63a3fc82
IEDL.DBID	7X8
ISICitedReferencesCount	157
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000331288000010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1522-9645
IngestDate	Sun Nov 09 12:17:02 EST 2025 Mon Jul 21 05:54:38 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	5
Keywords	High-sensitivity assayed troponin I MONICA Risk Genetics Archiving and Monograph (MORGAM) Mortality Cardiovascular risk Scottish Heart Health Extended Cohort (SHHEC)
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c365t-55fce7efe9c038b2ec20f4bce2e919d6e9114f15b07578c00d7a73bbe63a3fc82
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	24104876
PQID	1494303546
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1494303546 pubmed_primary_24104876
PublicationCentury	2000
PublicationDate	2014-02-01
PublicationDateYYYYMMDD	2014-02-01
PublicationDate_xml	– month: 02 year: 2014 text: 2014-02-01 day: 01
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	European heart journal
PublicationTitleAlternate	Eur Heart J
PublicationYear	2014
References	24357506 - Eur Heart J. 2014 Feb;35(5):268-70. doi: 10.1093/eurheartj/eht479.
References_xml	– reference: 24357506 - Eur Heart J. 2014 Feb;35(5):268-70. doi: 10.1093/eurheartj/eht479.
SSID	ssj0008616
Score	2.5184433
Snippet	Our aim was to test the prediction and clinical applicability of high-sensitivity assayed troponin I for incident cardiovascular events in a general...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	271
SubjectTerms	Biomarkers - blood Cardiovascular Diseases - blood Cardiovascular Diseases - mortality Cohort Studies Female Humans Immunoassay - methods Male Middle Aged Myocardial Infarction - blood Myocardial Infarction - mortality Prevalence Risk Assessment Scotland - epidemiology Sex Distribution Stroke - blood Stroke - mortality Troponin I - blood
Title	High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort
URI	https://www.ncbi.nlm.nih.gov/pubmed/24104876 https://www.proquest.com/docview/1494303546
Volume	35
WOSCitedRecordID	wos000331288000010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NaxRBEG3UiHjRaIxGk1CC12bno6d7xotoSFDIrgt-sLelP6rZFTKz7m4E_5C_06rpSXIKCF7q1jBM9VS_rnrznhBvbPCVJ-QrsfaFVM43sra5k75xOo-ogu0Vb76fm8mkns2a6dBw2wy0yqua2Bfq0HnukY8IySsqt5XS71Y_JbtG8XR1sNC4K3ZKgjJM6TKzG7XwWvfWp3REFbLRqhrGlHSJH-Hlmh2jtz9GuNiqTN8OMPuD5uzx_z7irng0QEx4n_bEE3EH26fiwXgYou-JP8ztgNW1cxes1qz5zZ84dBF8v2c8bNk_oV228AkuUiMxgPsNFljhWG6Y-J6cJ4Dwt6XYhrT2mt0KzFsHlvFI_0e-BUKbMP7MOirwYdldMDVoDdPUDIIvLBOx3CzgpFvQpeCZ-HZ2-vXkoxzsGqQvdbWVVRU9GozY-KysXYG-yCJlHwts8iZoirmKeeUy1tD3WRaMNaVzqEtbRl8X--Je27X4QkDmrEETVFCKQ-6wqUvvjTNWx0zXB-L1VQbm9DnwjMO22F1u5jc5OBDPUxrnq6TbMSewQvXK6Jf_sPqVeEjQSKVmy6HYiVQM8Ejc97_oRayP-31GcTId_wV3juPd
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High+population+prevalence+of+cardiac+troponin+I+measured+by+a+high-sensitivity+assay+and+cardiovascular+risk+estimation%3A+the+MORGAM+Biomarker+Project+Scottish+Cohort&rft.jtitle=European+heart+journal&rft.au=Zeller%2C+Tanja&rft.au=Tunstall-Pedoe%2C+Hugh&rft.au=Saarela%2C+Olli&rft.au=Ojeda%2C+Francisco&rft.date=2014-02-01&rft.issn=1522-9645&rft.eissn=1522-9645&rft.volume=35&rft.issue=5&rft.spage=271&rft_id=info:doi/10.1093%2Feurheartj%2Feht406&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-9645&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-9645&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-9645&client=summon